跳至主要内容
临床试验/ACTRN12612000665831
ACTRN12612000665831招募中2 期

In a population of patients receiving chronic warfarin therapy, what is the dose of oral vitamin K required to reverse 95% of the population to an INR<1.5 at 24 hours after a single dose administration and cessation of warfarin?

Dr Noel Chan0 个研究点目标入组 30 人开始时间: 2012年6月21日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Patients aged 18 years and older, capable of giving informed consent, who are receiving warfarin for the treatment of VTE and who are about to end anticoagulation or temporarily cease anticoagulation as they are deemed to be at low risk of thrombo-embolic recurrence.

排除标准

  • Any indications for the need for ongoing anticoagulation or high thromboembolic risk patients (e.g: AF, antiphospholipid syndrome, recurrent idiopathic VTE , Stroke or TIA).
  • Fat malabsorption syndromes, biliary atresia, pancreatic insufficiency.
  • Allergic reaction to Vitamin K and coconut oil.
  • Unstable INR, or recent INR<2, or INR>4
  • Pregnant women.

研究者

发起方
Dr Noel Chan

相似试验